ArticleJournal of nanobiotechnology2026
Drynaria roosii-derived exosome-like nanovesicles promote alveolar socket healing via activation of ITPR3-mediated calcium flux.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic discovery of immunomodulatory plant-derived nanoparticles reveals RNA-mediated macrophage reprogramming.Bioactive materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Alveolar socket healing post-extraction is accompanied by alveolar bone loss, which is negative to subsequent prosthetic rehabilitation. Plant-derived exosome-like nanovesicles are extracellular vehicles with great potential for disease treatment and are advantageous for drug delivery and absorption. Herein, we report the mineralization-promoting effects of Drynaria roosii-derived exosome-like nanovesicles (DRDENs) on osteoblasts and in a mouse alveolar socket healing model. DRDENs were isolated and characterized. Treatment with DRDENs increased the formation of calcium nodules and the expression of osteogenic differentiation markers (ALP, RUNX2, and OCN) in osteoblasts. Compounds analysis of DRDENs revealed a previously unexplored component, naringenin chalcone. We evaluated the properties of naringenin chalcone and its bioactivity on osteoblast differentiation. In vivo studies confirmed the safety and efficacy of DRDENs and naringenin chalcone in bone regeneration. The mechanism was demonstrated in which DRDENs were endocytosed by cells, and naringenin chalcone was released to interact with the inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) in the endoplasmic reticulum (ER), thereby activating downstream calcium flux to enhance bone formation. Additionally, chalcone isomerase (CHI), a key enzyme involved in naringenin chalcone production in Drynaria roosii, was purified and functionally identified as a type I CHI with weak II CHI activity. Our findings provided a novel strategy for alveolar socket healing and shed light on the function of CHI in Drynaria roosii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.